Enfamil maker Reckitt foresees US infant formula shortage until spring | Inquirer
 
 
 
 
 
 

Enfamil maker Reckitt foresees US infant formula shortage until spring

/ 10:49 AM December 01, 2022

The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to “persist” until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil.

Panicked parents had emptied the baby formula aisles earlier this year at supermarkets after former top U.S. manufacturer Abbott Laboratories recalled dozens of types of its Similac, Alimentum, and EleCare formulas in February.

The products, made at a plant in Michigan, were pulled after complaints of bacterial infections. Supermarkets like Target and Walgreens Boots Alliance were forced to limit their sales, putting pressure on the Biden administration to address the crisis.

The White House in May took steps to address the shortage, invoking the Defense Production Act to help manufacturers obtain the ingredients needed to ramp up supply.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Enfamil maker Reckitt foresees US infant formula shortage until spring

Enfamil maker Reckitt foresees US infant formula shortage until spring

Supplies have yet to return to normal since the peak of the crisis in May and June, despite the U.S.’s progress in replenishing stocks, said Robert Cleveland, Reckitt senior vice president of North America and Europe Nutrition.

“I suspect that will persist to some degree until the spring resets,” he said. “When we talk about the crisis we talk about the condition of the shelves and how they appear to consumers, and how well that shelf meets their needs.”

Rival manufacturer Perrigo Company Plc declined to comment, while Danone, maker of Aptamil, did not immediately respond to a request for comment.

ADVERTISEMENT

Since the Abbott recall, the share of Reckitt in the infant formula market has skyrocketed, making it the No.1 supplier in the United States.

The British company has yet to see its newfound popularity recede as Cleveland said it’s just over 50% of the market has “remained relatively unchanged” since earlier this year.

Enfamil maker Reckitt foresees US infant formula shortage until spring

Enfamil baby formula, produced by Mead Johnson, is seen in a supermarket as inflation continues to hit consumers amid continuing nationwide shortages in infant and toddler formula, in Los Angeles, California, U.S. May 27, 2022. REUTERS/Lucy Nicholson

Its top position has been further boosted by the United States saying it will temporarily cover the cost of baby formula for low-income families dependent on government discounts in states contracted with the company.

ADVERTISEMENT

Companies normally bid for state contracts to be the sole provider of baby formula for low-income families under the Women, Infants, and Children (WIC) program. They offer a “rebate” through discounts to the states in their bids.

The government’s intervention, aimed at incentivizing firms to boost supplies, effectively covers that rebate. Reckitt has said its formula factories operate 24/7, feeding more than 40% of all low-income WIC infants.

“Certainly at some point in the future, we expect they (the United States Department of Agriculture) will want to return the program to normal,” Cleveland said.

“What we’re telling them is to give us enough notice – to put, essentially, a date on the calendar….don’t try to shock the system by making it happen too quickly – give us time to adjust because we’ll have to adjust our production, we’ll have to adjust our distribution,” he said.

Want stories like this delivered straight to your inbox? Stay informed. Stay ahead. Subscribe to InqMORNING

Don't miss out on the latest news and information.
TAGS: milk, shortage
For feedback, complaints, or inquiries, contact us.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.




This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.